Geldanamycin (GA) is a potent anticancer compound in various animal tumor models. Its analogue, Allylamino-17-demethoxygeldanamycin, is currently evaluated in clinical trials for cancer therapy. GA can disrupt the association between heat shock protein (HSP) 90 and its client proteins, and cause the degradation of the client proteins including oncogene neu and met.
Incubation of GA with neu-overexpressing tumor induced cytotoxic T lymphocyte activity through the degradation of neu and presentation of fragments of neu with MHC class I (Figure) . Since cytotoxic T lymphocyte is essential for eradiation of cancer by DNA vaccine, we hypothesized that combination of GA and DNA vaccine targeting HSP90 clients may enhance therapeutic efficacy.
In this report, the efficacy of increasing doses of GA combined with DNA vaccine was investigated in a transplanted tumor constitutively overexpressing endogenous p185 neu . Low dose, but not high dose of GA could enhance therapeutic efficacy of neu DNA vaccine. The humoral immunity was similar, but higher CTL activity was induced in combination therapy. We then test the combination of met DNA vaccine and GA in the B16 melanoma in C57BL/6 mice, and found similar enhancing effect. This study point out two important concept. First, GA is a double-edged sword, can enhance DNA vaccine efficacy at low dose, but inhibit immune reaction at high dose. Secondly, DNA vaccine is appropriate for
